Fri, May 9, 11:06 AM (10 days ago)
**Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $10.1 million, up 170% from Q1 2024 ($3.7 million), driven by increased sales to Pfizer and Fiocruz. - **Profit Margins:** Operating loss narrowed to $4.1 million from $4.9 million in Q1 2024. - **Cash Flow:** Net cash used in operations was $5.1 million, with financing activities providing $5.1 million. - **Earnings:** Net loss of $3.6 million, improved from $4.6 million in Q1 2024. **Key Metrics:** - **Revenue Growth:** Significant increase in revenues from selling goods, particularly to Pfizer and Fiocruz. - **Cost Management:** Decrease in selling, general, and administrative expenses by 16%. - **Cash Position:** $34.7 million in cash and cash equivalents, sufficient for at least 12 months. **Trends and Uncertainties:** - **Commercialization:** Continued focus on commercializing Elfabrio and Elelyso. - **Clinical Trials:** Preparations for phase II clinical trial of PRX-115 in the second half of 2025. - **Geopolitical Risks:** Potential disruptions due to ongoing conflicts in Israel. **Future Operations Impact:** - **Product Pipeline:** Advancing PRX-115 and PRX-119 through clinical trials. - **Financial Strategy:** Plans to raise additional capital through equity offerings and strategic partnerships. - **Market Position:** Strengthening market presence for Elfabrio and Elelyso, with potential for new product approvals. **Conclusion:** Protalix BioTherapeutics showed strong revenue growth and improved operational efficiency in Q1 2025. The company is well-positioned to advance its product pipeline and commercialize its approved therapies, despite geopolitical uncertainties. The financial strategy focuses on maintaining liquidity and pursuing strategic partnerships to support future growth.